Lexicon Q4 net loss $30.5M; NDA for sotagliflozin on track for May PDUFA

LEXICON PHARMACEUTICALS, INC.

Net loss $30.5M ($0.16 per share) vs $25.6M ($0.17) in Q4 2021; full-year loss $101.9M ($0.62).
R&D expenses $14.0M (down from $16.5M); SG&A $16.3M (up from $8.8M) due to launch prep.
Cash and investments $138.4M as of Dec 31, 2022, up from $86.7M year-end 2021.
Sotagliflozin NDA for heart failure on track for May 2023 PDUFA date after FDA late-cycle review.
LX9211 showed consistent results in diabetic neuropathic pain; PHN study missed primary endpoint (p=0.12) but showed evidence of effect.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

LEXICON PHARMACEUTICALS, INC. reported the three months ended December 31, 2022 results: net income Net loss of $30.5 million, or $0.16 per share, EPS $0.16 per share.

Period: the three months ended December 31, 2022
Net income: Net loss of $30.5 million, or $0.16 per share
EPS: $0.16 per share
Result: reported results

Exact text from the filing

Net loss for the fourth quarter of 2022 was $30.5 million, or $0.16 per share, as compared to a net loss of $25.6 million, or $0.17 per share, in the corresponding period in 2021.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

LEXICON PHARMACEUTICALS, INC. reported the full-year ended December 31, 2022 results: net income Net loss of $101.9 million, or $0.62 per share, EPS $0.62 per share.

Period: the full-year ended December 31, 2022
Net income: Net loss of $101.9 million, or $0.62 per share
EPS: $0.62 per share
Result: reported results

Exact text from the filing

Net loss for the full-year 2022 was $101.9 million, or $0.62 per share, as compared to a net loss of $87.8 million, or $0.60 per share in 2021.

View on SEC.gov

Browse all earnings releases →

LEXICON PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001062822-23-000004

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.